# India Patient Derived Xenograft Model Market > India Patient-Derived Xenograft Model Market Research Report By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer), By Model Type (Mice, Rats) andBy End-User (Pharmaceutical, Biopharmaceutical Companies, Academic & Research Institutes, CROs, CDMOs) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 13.29% - **2024:** $ 12.64 Million - **2025:** $ 14.32 Million - **2035:** $ 49.89 Million - **Key Players:** Charles River Laboratories (US), Crown Bioscience (US), Horizon Discovery (GB), OncoOne (US), The Jackson Laboratory (US), XenoTech (US), Celerion (US), CureMetrix (US) **Report ID:** MRFR/HC/50976-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-patient-derived-xenograft-model-market-52736 --- ## Market Summary ## **India Patient-Derived Xenograft Model Market Overview** **As per MRFR analysis, the India Patient-Derived Xenograft Model Market Size was estimated at 11.3 (USD Million) in 2024. The India Patient-Derived Xenograft Model Market Industry is expected to grow from 12.8 (USD Million) in 2025 to 51.2 (USD Million) by 2035.** The India Patient-Derived Xenograft Model Market CAGR (growth rate) is expected to be around 13.431% during the forecast period (2025 - 2035). ## **Key India Patient-Derived Xenograft Model Market Trends Highlighted** The India Patient-Derived Xenograft (PDX) Model Market is witnessing significant growth driven by various key market drivers. The increasing prevalence of cancer in India, as highlighted in reports from the National Cancer Registry Programme, emphasizes the urgent need for better diagnostic and therapeutic options. The Indian government’s “National Health Mission” also aims to enhance healthcare delivery, which indirectly supports research in advanced therapeutic models such as PDX. Moreover, collaborations between Indian biotech firms and international pharmaceutical companies are on the rise, promoting research and development in this area. Opportunities for growth exist, especially in sectors such as personalized medicine and targeted therapies. As healthcare in India evolves, there’s a growing need for models that can provide more accurate representations of human tumors, allowing for improved drug efficacy testing. This presents a chance for Indian research institutions and companies to innovate and advance their capabilities in creating robust PDX models tailored to diverse patient demographics. In recent times, trends indicating a shift toward precision medicine are gaining traction in India. Studies reveal that there is increasing interest in the development of PDX models that reflect the multi-genomic nature of Indian cancer patients. Additionally, funding for research and development in biomedicine, including PDX technologies, is witnessing a boost due to government incentives and health programs that promote innovative healthcare solutions. The rise of biobanking in India also enhances the PDX Model Market, as it supports the availability of diverse tumor samples for research. Furthermore, advancements in technology related to gene editing and molecular profiling are paving the way for more sophisticated PDX models, which essential for advancing cancer therapies. Overall, these trends position the India [Patient-Derived Xenograft Model Market](../../../reports/patient-derived-xenograft-model-market-12128)for continued growth, emphasizing the importance of localized research and the need for tailored treatment approaches in the Indian healthcare landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **India Patient-Derived Xenograft Model Market Drivers** ### **Increasing Incidence of Cancer Cases in India** The rise in cancer cases in India has been a significant factor driving the growth of the India Patient-Derived Xenograft Model Market Industry. According to the National Cancer Registry Programme, there are over 1.16 million new cancer cases reported annually in India. This underscores the need for advanced research tools, including patient-derived xenograft models, which facilitate personalized medicine. Major organizations such as the Indian Council of Medical Research (ICMR) have acknowledged the increasing burden of cancer, pushing for enhanced Research and Development (R&D) initiatives. These initiatives are critical for developing more effective therapeutic strategies, highlighting the increasing demand for patient-derived xenograft models in India. ### **Growth in Biopharmaceutical Research** The biopharmaceutical sector in India is experiencing significant growth, with the country being one of the largest producers of generic drugs globally. The Department of Pharmaceuticals reports an increase in biopharma research investments, with an expected rise in funding for innovative drug development. This scenario is creating a higher demand for patient-derived xenograft models, as they are crucial for validating therapeutic efficacy in preclinical studies. BIRAC and other top organizations are fostering initiatives that promote the use of patient-derived models and drug discovery, which has been propelling the India Patient-Derived Xenograft Model Market Industry. ### **Technological Advancements in Xenograft Models** Technological advancements in cell culture techniques and genetic manipulation are significantly enhancing the efficacy of patient-derived xenografts. The Council of Scientific and Industrial Research (CSIR) has reported on the innovative developments in bioengineering that contribute to more accurate models reflecting patient tumors. These improvements are essential for obtaining precise data that drives the development of personalized medicine and targeted therapies. As more research institutions in India adopt these advanced techniques, the demand for patient-derived xenograft models in the India Patient-Derived Xenograft Model Market Industry is expected to rise. ## **India Patient-Derived Xenograft Model Market Segment Insights** ### **Patient-Derived Xenograft Model Market Tumor Type Insights** The Tumor Type segment of the India Patient-Derived Xenograft Model Market is crucial for understanding the dynamics of cancer research and treatment development in the country. As cancer rates rise, there is an increased focus on precision medicine and personalized treatment approaches, driving demand for patient-derived xenograft models which closely mimic human tumors. Lung cancer remains a significant concern, given high incidence and mortality rates associated with it in India. The growth in research around this tumor type underscores the need for innovative therapies and effective drug testing. Likewise, pancreatic cancer, often diagnosed at advanced stages due to its subtle symptoms, poses challenges that necessitate tailored models to explore new therapeutic avenues. Prostate cancer, the most common cancer among men in India, is entering a phase of heightened research efforts as awareness and screening measures improve, leading to a greater emphasis on developing models that can accurately represent this malignancy. Furthermore, breast cancer, which has seen increasing prevalence, is also a vital area of focus, as patient-derived xenografts can aid in studying tumor heterogeneity and treatment resistance. Other cancer types reveal a broad spectrum of research interests, reflecting the diverse oncological landscape in India. This segmentation illustrates the importance of niche research areas within the overall patient-derived xenograft framework, catering to the distinct biological behaviors and treatment challenges associated with each tumor type. In this landscape, market growth and development in the India Patient-Derived Xenograft Model Market signify a collective effort towards enhancing cancer research, improving outcomes, and ultimately transforming therapeutic strategies tailored for the Indian population. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Patient-Derived Xenograft Model Market Model Type Insights** The Model Type segment of the India Patient-Derived Xenograft Model Market is primarily categorized into Mice and Rats, both of which play distinct roles in preclinical research. Mice are favored for their small size, rapid life cycle, and genetic similarities to humans, making them ideal for various research and development purposes, especially in oncology and pharmacology. Their ease of handling and well-established genetic models further enhance their applicability in patient-derived xenograft applications. On the other hand, Rats provide advantages in studies requiring larger body mass, notably in pharmacokinetic profiling and toxicology assessments. The use of Rats is significant due to their advanced cognitive abilities, which make them suitable for neurological studies. As the pharmaceutical and biotechnological industries in India continue to expand, the demand for these model types remains robust, driven by the need for more effective drug development and personalized medicine. The growth of research institutions and the increasing focus on innovation in treatment modalities underscore the critical importance of these models in India’s evolving biomedical landscape. Overall, the emphasis on both Mice and Rats highlights their complementary roles in enhancing the efficiency and accuracy of preclinical testing. ### **Patient-Derived Xenograft Model Market End-User Insights** The India Patient-Derived Xenograft Model Market, particularly in the End-User segment, showcases a diverse landscape crucial for advancing healthcare solutions. Pharmaceutical and biopharmaceutical companies are at the forefront, leveraging patient-derived models to optimize drug development and enhance targeted therapies. Their significant investment in Research and Development activities drives innovation, leading to improved therapeutic outcomes. Academic and research institutes also play a pivotal role, focusing on fundamental research and novel therapies that utilize these xenograft models to study disease mechanisms and treatment responses. Clinical Research Organizations (CROs) contribute by providing specialized services that facilitate the efficient management of clinical trials involving these models, which accelerates the drug development process. Contract Development and Manufacturing Organizations (CDMOs) support these end-users by offering scalable production techniques that meet regulatory standards. The ongoing trend towards personalized medicine and the rise in chronic diseases in India are key growth drivers, enhancing the demand for patient-derived xenograft models across various applications in the healthcare sector. With a robust increase in investment in biotechnology and active collaborations between industry and academia, the India Patient-Derived Xenograft Model Market is positioned for significant growth in the foreseeable future. ## **India Patient-Derived Xenograft Model Market Key Players and Competitive Insights** The India Patient-Derived Xenograft Model Market has witnessed significant growth and development, characterized by both emerging and established entities navigating a complex landscape of biomedical research and drug development. This market is driven by the increasing demand for personalized medicine, cancer research, and drug screening processes that require advanced in vivo models for efficacy and safety studies. A pivotal factor influencing competition is the innovation of technologies that facilitate the creation of more representative and reliable patient-derived xenograft models, which enhance the translational value of preclinical research. Companies in this market are focusing on partnerships, strategic acquisitions, and collaborations with research institutions to leverage expertise and enhance their product portfolios, thus fostering a competitive edge in the evolving healthcare ecosystem in India. Bioneer Corporation has established a noteworthy presence in the India Patient-Derived Xenograft Model Market. The company leverages its capabilities in molecular biology and biotechnology to offer unique solutions tailored for cancer research through PDX models. Bioneer's strength lies in its commitment to high-quality research outputs and its robust network within the scientific community, positioning it well against competitors. The company's focus on developing innovative models and dedicated customer support also contributes to its competitive advantage, making it a trusted choice among researchers and clinical institutions exploring patient-specific treatment options in India. This focus on innovation and customer engagement allows Bioneer Corporation to strengthen its foothold in the market. Horizon Discovery operates effectively within the India Patient-Derived Xenograft Model Market by delivering essential tools and services that aid scientific research and drug development. The company offers a diversified portfolio that includes genetically engineered cell lines and advanced PDX models, enhancing its market presence significantly. Horizons' strengths are highlighted through its strong emphasis on innovation, high-quality product offerings, and a commitment to addressing specific research needs within the Indian market context. The company has also engaged in strategic partnerships and collaborations, enhancing its capabilities and expanding its reach in terms of customer engagement. Additionally, any mergers and acquisitions pursued by Horizon Discovery further solidify its position and enable it to enhance its product offerings to the unique needs of the Indian healthcare landscape, driving greater advancements in personalized medicine and research outcomes. ### **Key Companies in the India Patient-Derived Xenograft Model Market Include** ## **India Patient-Derived Xenograft Model Market Industry Developments** Recent developments in the India Patient-Derived Xenograft Model Market have seen notable growth due to advancements in cancer research and personalized medicine. Companies such as Bioneer Corporation and Horizon Discovery continue to innovate, enhancing the accuracy of xenograft models for preclinical studies. In September 2022, Celerion expanded its services in India, catering to the growing demand for patient-derived models, while Crown Bioscience reported increased collaborations with Indian biotech firms to enhance their R&D capabilities. Notable mergers and acquisitions include Thermo Fisher Scientific's acquisition of a biotech firm in July 2023, which complements its patient-derived xenograft portfolio. This move has been viewed positively, leading to a boost in stock valuation for Thermo Fisher Scientific as it enhances its market share within India. Additionally, Eli Lilly and Company has initiated partnerships with local research institutions to further develop their patient-derived models, reflecting the growing emphasis on localized solutions. The market has been influenced significantly over the last two years, with increased investments and governmental support for biomedical research contributing to an expanding landscape for patient-derived xenograft technologies in India. ## **India Patient-Derived Xenograft Model Market Segmentation Insights** ### **Patient-Derived Xenograft Model Market Tumor Type Outlook** ### **Patient-Derived Xenograft Model Market Model Type Outlook** ### **Patient-Derived Xenograft Model Market End-User Outlook** - Pharmaceutical - Biopharmaceutical Companies - Academic & Research Institutes - CROs - CDMOs ## Market Drivers ### Increasing Research Funding The patient derived-xenograft-model market in India is experiencing a surge in research funding from both governmental and private sectors. This influx of financial resources is likely to enhance the development of innovative cancer therapies and personalized medicine approaches. In 2025, the Indian government allocated approximately $1.5 billion to cancer research initiatives, which is expected to bolster the capabilities of research institutions and biotechnology firms. As a result, the patient derived-xenograft-model market is poised for growth, as these models are essential for preclinical testing and understanding tumor biology. The increased funding may also facilitate collaborations between academic institutions and industry players, further driving advancements in this market. ### Collaborative Research Initiatives Collaborative research initiatives between academic institutions and industry players are becoming more prevalent in India, which is likely to benefit the patient derived-xenograft-model market. These partnerships facilitate the sharing of resources, expertise, and data, leading to accelerated advancements in cancer research. For instance, several universities have established partnerships with biotechnology firms to develop innovative cancer therapies using patient derived-xenograft models. Such collaborations not only enhance the quality of research but also increase the visibility and application of these models in clinical settings. As these initiatives continue to grow, the patient derived-xenograft-model market is expected to expand accordingly. ### Rising Awareness of Cancer Research There is a notable increase in awareness regarding cancer research and its significance in India, which is positively impacting the patient derived-xenograft-model market. Educational campaigns and initiatives by non-profit organizations and healthcare institutions are fostering a better understanding of cancer biology and treatment options among the general public. This heightened awareness is likely to lead to increased participation in clinical trials and research studies, thereby driving demand for patient derived-xenograft models. As more patients become informed about their treatment options, the market may see a rise in the utilization of these models for developing targeted therapies. ### Expansion of Biopharmaceutical Sector The biopharmaceutical sector in India is expanding rapidly, which is likely to have a favorable impact on the patient derived-xenograft-model market. With the increasing number of biopharmaceutical companies focusing on oncology, there is a growing need for reliable preclinical models to test new drug candidates. The biopharmaceutical market in India is projected to reach $100 billion by 2025, indicating a robust growth trajectory. This expansion is expected to drive investments in research and development, thereby increasing the demand for patient derived-xenograft models as essential tools for drug discovery and development. ### Growing Demand for Personalized Medicine There is a growing demand for personalized medicine in India. As healthcare providers increasingly recognize the importance of tailoring treatments to individual patients, the need for effective preclinical models becomes paramount. Patient derived-xenograft models allow researchers to study the unique characteristics of tumors from individual patients, leading to more effective treatment strategies. This trend is supported by a report indicating that the personalized medicine market in India is projected to reach $10 billion by 2026, reflecting a compound annual growth rate (CAGR) of 12%. Consequently, This market is likely to benefit from this shift towards personalized healthcare solutions. ## Future Outlook The [Patient Derived Xenograft Model Market](https://www.marketresearchfuture.com/reports/patient-derived-xenograft-model-market-12128) is projected to grow at a 13.29% CAGR from 2025 to 2035, driven by advancements in personalized medicine and increasing R&D investments. **New opportunities:** - Development of specialized PDX models for rare cancers - Partnerships with biotech firms for co-development - Expansion of biorepository services for patient samples By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic collaborations. ## Segment Insights ### By Tumor Type: Lung Cancer (Largest) vs. Breast Cancer (Fastest-Growing) In the India patient derived-xenograft-model market, lung cancer accounts for the largest share, reflecting the high incidence and prevalence of this disease in the region. It significantly dominates the tumor type segment, showcasing the critical need for effective treatment models. Conversely, other cancers like pancreatic and prostate are also represented but with a smaller share compared to lung and breast cancer. The growth trends in the segment reveal that breast cancer is emerging as the fastest-growing area within the market. This increase can be attributed to several factors, including greater awareness of the disease, advancements in research, and the rising number of patient registrations for clinical trials. These elements are driving innovation and investment in patient-derived xenograft models specifically aimed at breast cancer treatment. Lung Cancer: Dominant vs. Breast Cancer: Emerging Lung cancer remains a dominant force within the India patient derived-xenograft-model market, characterized by high demand for personalized treatment approaches and extensive research funding. This segment benefits from established pipeline drugs and extensive clinical data that underscore its relevance. On the other hand, breast cancer, now recognized as an emerging segment, is experiencing a rapid upswing due to increasing incidences and a proactive stance towards early detection and treatment. The growing focus on individualized therapy, particularly through innovative xenograft models, is expected to bolster this market, as stakeholders aim to address the unique biological behaviors of breast tumors. ### By Model Type: Mice (Largest) vs. Rats (Fastest-Growing) In the India patient derived-xenograft-model market, the distribution of model types shows a clear preference for mice, which dominate the market share due to their well-established use in preclinical studies. Mice models make up a significant portion of the research and development processes, providing researchers with reliable data and insights. Conversely, rat models, while smaller in share, are being increasingly recognized for their utility in specific areas of research and are on an upward trend. The growth of the rat model segment can be attributed to various factors including advancements in genetic manipulation techniques and the need for models that better mimic human diseases. As researchers look for more relevant data for therapeutic developments, the demand for rats is gaining momentum, marking them as the fastest-growing segment in this market. Their physiological and behavioral characteristics make them suitable for numerous drug testing and efficacy studies, complementing the traditional reliance on mice models. Model Type: Mice (Dominant) vs. Rats (Emerging) Mice have long been the dominant model in the India patient derived-xenograft-model market due to their extensive genetic and biological similarity to humans, which makes them ideal for preclinical research. Their established protocols and availability make them a preferred choice for researchers. On the other hand, rats are emerging as an important alternative because of their larger body size, which allows for more complex surgical and therapeutic interventions. As the focus shifts towards more representative models that enhance translational research, rats are gaining prominence. This shift is driven by the need for improved understanding of diseases and the effects of treatments in a manner that closely reflects human conditions. ### By End-user: Pharmaceutical and Biopharmaceutical Companies (Largest) vs. Academic & Research Institutes (Fastest-Growing) In the India patient derived-xenograft-model market, the distribution of market share among end-users reveals that pharmaceutical and biopharmaceutical companies hold the largest portion due to their high demand for innovative therapeutic solutions. Conversely, academic and research institutes represent the fastest-growing segment, as their focus on novel research methodologies and academic advancements drive increasing investments into patient-derived xenograft models. Growth trends indicate that the pharmaceutical and biopharmaceutical companies are expanding their collaborative efforts with academic institutions to foster innovation in drug development. Additionally, the rising trend of precision medicine has bolstered the demand for patient-derived xenograft models as research institutes increasingly adopt these models to enhance their studies. The integration of cutting-edge technologies further fuels this dynamism in the market. Pharmaceutical and Biopharmaceutical Companies (Dominant) vs. CROs & CDMOs (Emerging) Pharmaceutical and biopharmaceutical companies dominate the India patient derived-xenograft-model market due to their extensive R&D investments and a strong demand for personalized medicine solutions. This segment greatly benefits from partnerships with CROs and CDMOs who provide specialized expertise and resources in drug development processes. As an emerging segment, CROs and CDMOs are increasingly recognized for their critical role in driving efficiency and innovation, facilitating the rapid advancement of pharmaceutical research and product development. The growth of CROs is supported by a surge in outsourcing activities from pharmaceutical companies seeking to optimize costs and enhance operational scalability. Together, these segments represent a dynamic interplay that is shaping the future landscape of the market. ## Competitive Benchmarking The patient derived-xenograft-model market is currently characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine and advancements in oncology research. Key players such as Charles River Laboratories (US), Crown Bioscience (US), and Horizon Discovery (GB) are strategically positioned to leverage their expertise in preclinical models and drug development. Charles River Laboratories (US) focuses on innovation through continuous investment in R&D, enhancing their portfolio of patient-derived xenograft models. Meanwhile, Crown Bioscience (US) emphasizes partnerships with biopharmaceutical companies to expand their service offerings, thereby enhancing their market presence. Horizon Discovery (GB) appears to be concentrating on digital transformation, integrating advanced technologies into their operations to streamline processes and improve model accuracy. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and collaboration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for diverse offerings, yet the influence of key players remains significant, as they set industry standards and drive technological advancements. In October Charles River Laboratories (US) announced a strategic partnership with a leading biopharmaceutical firm to develop novel patient-derived xenograft models tailored for specific cancer types. This collaboration is likely to enhance their capabilities in personalized medicine, positioning them as a leader in the market. The partnership underscores the importance of collaboration in advancing research and development in oncology. In September Crown Bioscience (US) expanded its operations in India by establishing a new facility dedicated to patient-derived xenograft models. This move is indicative of their commitment to regional expansion and reflects the growing demand for localized solutions in drug development. The facility is expected to enhance their service delivery and reduce turnaround times for clients in the region. In August Horizon Discovery (GB) launched a new suite of digital tools designed to improve the accuracy and efficiency of patient-derived xenograft models. This initiative highlights the increasing integration of technology in the market, as companies seek to enhance their offerings through digital solutions. The launch is anticipated to attract a broader client base, particularly those focused on precision medicine. As of November current trends in the patient derived-xenograft-model market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in research processes. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This shift suggests that companies that prioritize R&D and strategic partnerships will be better positioned to thrive in the evolving market. ## Recent News & Developments Recent developments in the India Patient-Derived Xenograft Model Market have seen notable growth due to advancements in cancer research and personalized medicine. Companies such as Bioneer Corporation and Horizon Discovery continue to innovate, enhancing the accuracy of xenograft models for preclinical studies. In September 2022, Celerion expanded its services in India, catering to the growing demand for patient-derived models, while Crown Bioscience reported increased collaborations with Indian biotech firms to enhance their R&D capabilities. Notable mergers and acquisitions include Thermo Fisher Scientific's acquisition of a biotech firm in July 2023, which complements its patient-derived xenograft portfolio. This move has been viewed positively, leading to a boost in stock valuation for Thermo Fisher Scientific as it enhances its market share within India. Additionally, Eli Lilly and Company has initiated partnerships with local research institutions to further develop their patient-derived models, reflecting the growing emphasis on localized solutions. The market has been influenced significantly over the last two years, with increased investments and governmental support for biomedical research contributing to an expanding landscape for patient-derived xenograft technologies in India. ## Report Scope | MARKET SIZE 2024 | 12.64(USD Million) | | --- | --- | | MARKET SIZE 2025 | 14.32(USD Million) | | MARKET SIZE 2035 | 49.89(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.29% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Charles River Laboratories (US), Crown Bioscience (US), Horizon Discovery (GB), OncoOne (US), The Jackson Laboratory (US), XenoTech (US), Celerion (US), CureMetrix (US) | | Segments Covered | Tumor Type, Model Type, End-user | | Key Market Opportunities | Advancements in personalized medicine drive demand for innovative patient derived-xenograft-model solutions. | | Key Market Dynamics | Rising demand for personalized medicine drives growth in the patient derived-xenograft-model market amid evolving regulatory frameworks. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current market valuation of the patient derived-xenograft-model market in India?** A: The market valuation was $12.64 Million in 2024. **Q: What is the projected market size for the patient derived-xenograft-model market in India by 2035?** A: The projected market size is $49.89 Million by 2035. **Q: What is the expected CAGR for the patient derived-xenograft-model market in India during the forecast period 2025 - 2035?** A: The expected CAGR is 13.29% during the forecast period 2025 - 2035. **Q: Which tumor type has the highest market valuation in the patient derived-xenograft-model market?** A: Breast Cancer has the highest market valuation at $3.79 Million in 2024. **Q: What are the two primary model types used in the patient derived-xenograft-model market?** A: The primary model types are Mice, valued at $5.06 Million, and Rats, valued at $7.58 Million in 2024. **Q: Who are the key players in the patient derived-xenograft-model market?** A: Key players include Charles River Laboratories, Crown Bioscience, and Horizon Discovery, among others. **Q: What is the market valuation for pancreatic cancer in the patient derived-xenograft-model market?** A: The market valuation for pancreatic cancer was $1.9 Million in 2024. **Q: Which end-user segment holds the highest market valuation in the patient derived-xenograft-model market?** A: Pharmaceutical and Biopharmaceutical Companies hold the highest market valuation at $5.06 Million in 2024. **Q: What is the market valuation for prostate cancer in the patient derived-xenograft-model market?** A: The market valuation for prostate cancer was $2.53 Million in 2024. **Q: What is the market valuation for other cancers in the patient derived-xenograft-model market?** A: The market valuation for other cancers was $1.89 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-patient-derived-xenograft-model-market-52736*